Wednesday, January 15, 2025 1/15/2025

The unleashed microbiome of cancer patients as a discovery platform for rational microbiome engineering

Award Number: DP2AI164318
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary The human gut microbiome is associated with a range of diseases, and may positively or negatively affect the success of therapies. However, the causal directions between the human gut microbiome and host health are seldomly clear due to a lack of feasible controlled experiments in humans. High resolution, high frequency temporal data of paired microbiome and physiological measurement, and rich metadata of potential confounders, allow the application of causal inference frameworks. Such data can be mined for potential microbiome drivers of host health, especially if both the microbiome and host physiology are perturbed during the time courses. We have recently published a vast longitudinal microbiome set from cancer patients undergoing severe perturbation of their immune system. Concurrently, these patients experience dramatic shifts in their gut ecosystem. We here propose to unlock this data and build a discovery platform for microbiome causality, towards rational microbiome engineering. We will develop a new machine-learning technique that enables rapid exploration of our data through effective visualization and a web-based interface. We will develop a new method to identify gut microbial competitor species of common pathogens, which are systematically missed by existing approaches but are representing the most promising targets for microbiome engineering. Finally, we will elucidate the bidirectional interplay between human- targeted medications and the gut microbiome. For this, we will leverage our large data set of paired microbiome and host immune cell trajectories. This will validate recent in vitro results indicating that human-targeted medications may influence gut ecology using in situ data, and it will identify potential gut microbiome modulation of pharmacokinetics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $508,500 )
2024	2024	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Allergy and Infectious Diseases Research	000	4	7/9/2024	NON-COMPETING CONTINUATION	$508,500
														Subtotal = $508,500

Issue Date FY: 2023 ( Subtotal = $508,500 )
2023	2023	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Allergy and Infectious Diseases Research	000	3	7/11/2023	NON-COMPETING CONTINUATION	$508,500
														Subtotal = $508,500

Issue Date FY: 2022 ( Subtotal = $508,500 )
2022	2022	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Allergy and Infectious Diseases Research	000	2	7/26/2022	NON-COMPETING CONTINUATION	$508,500
														Subtotal = $508,500

Issue Date FY: 2021 ( Subtotal = $508,500 )
2021	2021	NEW YORK UNIVERSITY	550 1ST AVE	NEW YORK	NY	10016	NEW YORK	USA	Allergy and Infectious Diseases Research	000	1	8/12/2021	NEW	$508,500
														Subtotal = $508,500

Grand Total All Awards = $2,034,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The unleashed microbiome of cancer patients as a discovery platform for rational microbiome engineering

Award Number: DP2AI164318

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer